Literature DB >> 21995544

Formulation approaches in enhancement of patient compliance to oral drug therapy.

Aliasgar Shahiwala1.   

Abstract

INTRODUCTION: Disease management of outdoor patients is mainly affected by patient compliance to the drug therapy, which in turn is governed by patient convenience. Failure to follow through with a treatment decision is one of the biggest causes of unsuccessful medical care. At present, different formulation options are available for various drugs, and hence, the decision is based on the most convenient dosage form for the patient, along with optimum therapeutic benefits. AREAS COVERED: This paper reviews various available formulation approaches, in the hope of improving patient convenience, compliance and the overall outcome of oral drug therapy. EXPERT OPINION: While parenterals are valued for their speed and efficiency of delivery, these systems generally score low on patient satisfaction surveys. The oral route is the preferred route for drug delivery, although it renders multiple obstacles to formulate a patient-convenient platform, such as unfavorable taste and swallowing difficulties. Transdermal drug delivery also provides high patient satisfaction, but is effective only for the delivery of smaller, lipophilic molecules. The increasing development of biopharmaceutical therapies renders an increasing number of challenges for formulation scientists to develop a more patient-convenient means of drug delivery.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21995544     DOI: 10.1517/17425247.2011.628311

Source DB:  PubMed          Journal:  Expert Opin Drug Deliv        ISSN: 1742-5247            Impact factor:   6.648


  14 in total

1.  Development and evaluation of an oral fast disintegrating anti-allergic film using hot-melt extrusion technology.

Authors:  Manjeet B Pimparade; Anh Vo; Abhijeet S Maurya; Jungeun Bae; Joseph T Morott; Xin Feng; Dong Wuk Kim; Vijay I Kulkarni; Roshan Tiwari; K Vanaja; Reena Murthy; H N Shivakumar; D Neupane; S R Mishra; S N Murthy; Michael A Repka
Journal:  Eur J Pharm Biopharm       Date:  2017-06-06       Impact factor: 5.571

2.  Oral administration of GZ-793A, a VMAT2 inhibitor, decreases methamphetamine self-administration in rats.

Authors:  Carrie E Wilmouth; Guangrong Zheng; Peter A Crooks; Linda P Dwoskin; Michael T Bardo
Journal:  Pharmacol Biochem Behav       Date:  2013-09-26       Impact factor: 3.533

Review 3.  Physical approaches to masking bitter taste: lessons from food and pharmaceuticals.

Authors:  John N Coupland; John E Hayes
Journal:  Pharm Res       Date:  2014-09-10       Impact factor: 4.200

4.  The opiate dosage adequacy scale for identification of the right methadone dose--a prospective cohort study.

Authors:  Stephan Walcher; John Koc; Volker Reichel; Frank Schlote; Uwe Verthein; Jens Reimer
Journal:  BMC Pharmacol Toxicol       Date:  2016-04-07       Impact factor: 2.483

5.  Hydrocortisone/cyclodextrin complex electrospun nanofibers for a fast-dissolving oral drug delivery system.

Authors:  Asli Celebioglu; Tamer Uyar
Journal:  RSC Med Chem       Date:  2020-01-08

6.  Long-Acting Metformin Vs. Metformin Immediate Release in Patients With Type 2 Diabetes: A Systematic Review.

Authors:  Jixue Tan; Yang Wang; Song Liu; Qingyang Shi; Xu Zhou; Yiling Zhou; Xiaoling Yang; Pingshan Chen; Sheyu Li
Journal:  Front Pharmacol       Date:  2021-05-17       Impact factor: 5.810

7.  Pharmaceutical and pharmacokinetic characterization of a novel sublingual buprenorphine/naloxone tablet formulation in healthy volunteers.

Authors:  Andreas Fischer; Martin Jönsson; Peter Hjelmström
Journal:  Drug Dev Ind Pharm       Date:  2013-10-07       Impact factor: 3.225

8.  A novel quantified bitterness evaluation model for traditional Chinese herbs based on an animal ethology principle.

Authors:  Xue Han; Hong Jiang; Li Han; Xi Xiong; Yanan He; Chaomei Fu; Runchun Xu; Dingkun Zhang; Junzhi Lin; Ming Yang
Journal:  Acta Pharm Sin B       Date:  2017-09-13       Impact factor: 11.413

Review 9.  Developing a new class of engineered live bacterial therapeutics to treat human diseases.

Authors:  Mark R Charbonneau; Vincent M Isabella; Ning Li; Caroline B Kurtz
Journal:  Nat Commun       Date:  2020-04-08       Impact factor: 14.919

Review 10.  Volatile molecules for COVID-19: A possible pharmacological strategy?

Authors:  Cristiano Colalto
Journal:  Drug Dev Res       Date:  2020-07-19       Impact factor: 4.360

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.